#oncology #Atossa Therapeutics #Clinical Stage

Atossa Therapeutics Completes $16.5 Million Registered Direct Offering

Atossa Therapeutics, Inc. (Nasdaq: ATOS), known for its pioneering work in biopharmaceuticals, has announced the successful closure of a registered direct offering that raises up to $16.5 million. This offering is critical for the Seattle-based firm as it develops cutting-edge solutions targeting oncology and other critical health challenges.

Overview of the Offering

The direct offering included the sale of 1,363,637 shares of common stock along with accompanying warrants. The initial proceeds from this transaction were approximately $4.5 million, which will significantly support Atossa's ongoing clinical trials and other operational needs. Furthermore, there is potential for an additional $12 million in gross proceeds if the associated warrants are fully exercised. This aspect of the offering underscores Atossa's strategic financial planning.

Rodman & Renshaw LLC served as the exclusive placement agent for this deal, highlighting the growing interest and confidence in Atossa's innovative therapeutic pipeline.

Purpose of the Capital Raise

The funds obtained from the offering are earmarked for various strategic purposes, including the clinical development of Atossa’s flagship product candidate, (Z)-endoxifen, along with general corporate expenses. With a focus on oncology, Atossa aims to address significant unmet medical needs, especially in areas such as breast cancer treatment. The firm’s commitment to advancing its products through clinical development is unwavering, and this funding will play a pivotal role in achieving those goals.

Regulatory Compliance and Approach

The securities involved in this offering were made available through a